Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT04805957

Validation Digital Bio-markers During Sulforaphane Treatment.

The purpose of the research is to determine if changes seen during sulforaphane treatment (a compound that comes from eating certain vegetables) can better be understood using digital biomarkers. These digital biomarkers are things like heart rate, muscle movement etc. and are measured using non-invasive devices (like a watch) and are aimed at complementing the traditional clinical scores already in use in current trials (e.g. Aberrant Behavior Checklist (ABC), Social Responsiveness Scale (SRS) and Ohio Autism Clinical Impressions Scale (OACIS)).

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Autism Autism Spectrum Disorder Autistic Disorder Child Development Disorders, Pervasive Mental Disorders Neurodevelopmental Disorders

Age range

13 year–30 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Rutgers-RWJMS Department of Neurology

Piscataway, New Jersey, 08854, United States

About this study

This study is a pilot open label treatment trial with SF (sulforaphane) in 10 individuals that have completed with moderate to severe autism, age 13-30 years that have completed participation in ClinicalTrials.gov Identifier: NCT02677051. This study will measure digital biomarkers of the nervous systems. Digital biomarkers are obtained by using non-invasive wireless (wearable, like wearing a watch) biosensors that co-register in tandem multiple biorhythms self-generated by the person's nervous systems. These sensors gather a very large amount of data from measures such as EEG (electroencephalogram), EKG (electrocardiogram), kinematics and others. These measures are done at the same time as the clinical evaluations and so results can be compared. Because the data are based on the unique fingerprint-like signatures of the person's nervous systems, it is possible to ascertain the person's progression in response to treatment and compare it to baseline states. The project will also compare these self-emerging clusters between subjects, possibly identifying patterns that correlate with sub-phenotypes or with similarities in response to treatment. Changes in things such as natural behaviors, an individual's ability or desire to interact socially and ability or desire to communicate will alter the signature profiles from baseline. Since these changes are dynamic in nature, trends of the evolving patterns and separate changes that are a consequence of the treatment vs. changes that are part of the natural neurodevelopment can be detected. This may be a valuable tool in future studies of underlying etiology. The technology used to perform these measures and the software to analyze the data are evolving rapidly. Last, with the characterized signatures and possibly overlapping patterns generated in this and in other projects it is foreseeable that a clinically relevant tool for measures in autism will follow.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Autistic disorder diagnosis.
  • Age between 13-30 years.
  • Male gender.
  • Participated in clinical trial NCT02677051

Exclusion criteria

  • Those that started or continued taking Avmacol® or similar broccoli extracts since leaving our double-blind study.
  • Absence of a parent or legal guardian and consent,
  • Those that can not or will not complete all visits and adherence to study regimen.
  • Seizure within 2 years of screening,
  • History of chronic kidney, liver or thyroid disease.
  • Impaired renal function (serum creatinine> 1.2 mg/dl).
  • Impaired hepatic function (> 2x upper limit of normal).
  • Impaired thyroid function (TSH outside normal limits).
  • Current infection or treatment with antibiotics.
  • Chronic medical disorder (e.g., cardiovascular disease, stroke or diabetes) or major surgery within 3 months prior to enrollment.
  • Less than 13 years or more than 30 years of age.
  • Female gender.
  • A diagnosis of autism spectrum disorder other than autistic disorder, for example, Asperger, PDD-NOS ( Pervasive Developmental Disorder-Not Otherwise Specified) etc.

Treatment and study plan

Sulforaphane

Dietary Supplement

Sulforaphane comes from eating certain cruciferous vegetables. In this case the pills are made from broccoli seeds.

Other names: Avmacol®

Primary outcomes

  1. Aberrant Behavior Checklist (ABC)

    Time frame: Baseline.

    Rating scale to measure severity aberrant behaviors

  2. Aberrant Behavior Checklist (ABC)

    Time frame: Week 6.

    Rating scale to measure severity aberrant behaviors

  3. Aberrant Behavior Checklist (ABC)

    Time frame: Week 12, end of treatment.

    Rating scale to measure severity aberrant behaviors

  4. Aberrant Behavior Checklist (ABC)

    Time frame: Week 16.

    Rating scale to measure severity aberrant behaviors

  5. Social Responsiveness Scale (SRS)

    Time frame: Baseline.

    Rating scale to measure social interaction.

  6. Social Responsiveness Scale (SRS)

    Time frame: Week 6.

    Rating scale to measure social interaction.

  7. Social Responsiveness Scale (SRS)

    Time frame: Week 12, end of treatment.

    Rating scale to measure social interaction.

  8. Social Responsiveness Scale (SRS)

    Time frame: Week 16.

    Rating scale to measure social interaction.

  9. Ohio Autism Clinical Global Impression Scale - Severity (OACIS-S, an autism specific version of the Clinical Global Impression, CGI)

    Time frame: Baseline.

    Rating scale to measure autism severity and changes in severity.

  10. Ohio Autism Clinical Global Impression Scale - Severity (OACIS-S, an autism specific version of the Clinical Global Impression, CGI)

    Time frame: Week 6.

    Rating scale to measure autism severity and changes in severity.

  11. Ohio Autism Clinical Global Impression Scale - Severity (OACIS-S, an autism specific version of the Clinical Global Impression, CGI)

    Time frame: Week 12, end of treatment.

    Rating scale to measure autism severity and changes in severity.

  12. Ohio Autism Clinical Global Impression Scale - Severity (OACIS-S, an autism specific version of the Clinical Global Impression, CGI)

    Time frame: Week 16.

    Rating scale to measure autism severity and changes in severity.

  13. Digital Biomarkers

    Time frame: Baseline.

    Non-invasive biosensor measurements of micro-movements.

  14. Digital Biomarkers

    Time frame: Week 6.

    Non-invasive biosensor measurements of micro-movements.

  15. Digital Biomarkers

    Time frame: Week 12, end of treatment.

    Non-invasive biosensor measurements of micro-movements.

  16. Digital Biomarkers

    Time frame: Week 16.

    Non-invasive biosensor measurements of micro-movements.

  17. EEG

    Time frame: Baseline

    Electroencephalogram (EEG) measures electrical activity of the brain.

  18. EEG

    Time frame: Week 6.

    Electroencephalogram (EEG) measures electrical activity of the brain.

  19. EEG

    Time frame: Week 12, end of treatment.

    Electroencephalogram (EEG) measures electrical activity of the brain.

  20. EEG

    Time frame: Week 16.

    Electroencephalogram (EEG) measures electrical activity of the brain.

  21. EKG

    Time frame: Baseline

    Electrocardiogram (ECG or EKG) measures electrical signals from the heart.

  22. EKG

    Time frame: Week 6.

    Electrocardiogram (ECG or EKG) measures electrical signals from the heart.

  23. EKG

    Time frame: Week 12, end of treatment.

    Electrocardiogram (ECG or EKG) measures electrical signals from the heart.

  24. EKG

    Time frame: Week 16.

    Electrocardiogram (ECG or EKG) measures electrical signals from the heart.

  25. Electrophysiological recordings.

    Time frame: Baseline

    Measurement of electrical activity in Tissue.

  26. Electrophysiological recordings.

    Time frame: Week 6.

    Measurement of electrical activity in Tissue.

  27. Electrophysiological recordings.

    Time frame: Week 12, end of treatment.

    Measurement of electrical activity in Tissue.

  28. Electrophysiological recordings.

    Time frame: Week 16.

    Measurement of electrical activity in Tissue.

Sponsors and collaborators

Lead sponsor

Rutgers, The State University of New Jersey

Other

Registry information

Official study title

A Pilot Project to Validate Digital Bio-markers as a Tool to Measure Improvement in Core Symptoms of Autism During Sulforaphane Treatment.

Important dates

Study start
2022
Primary completion
2026
Study completion
2027
First posted
Mar 18, 2021
Registry last updated
Oct 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.